PTEN公司
癌症研究
蛋白激酶B
小RNA
癌基因
PI3K/AKT/mTOR通路
多发性骨髓瘤
转染
细胞凋亡
下调和上调
生物
细胞生长
细胞培养
细胞周期
免疫学
基因
遗传学
作者
Xiaoying Zhang,Yafang Chen,Pan Zhao,Li Zang,Zhiqing Zhang,Xiaofang Wang
标识
DOI:10.1080/10428194.2016.1213827
摘要
MicroRNAs (miRNAs) are involved in human cancers including myeloma. MiR-19a is one of the oncogenic miR-17-92 clusters, which is identified as a key oncogenic component in many cancers. Nevertheless, the function of miR-19a in myeloma has not been totally elucidated. The purpose of this study is to investigate the biological functions of miR-19a in MM. In vitro, we detected that the miR-19a-3p is overexpressed in myeloma cells. The proliferation and invision of myeloma cells are analyzed by MTT and BD matrigel assays, respectively. Western blot was performed to evaluate the expression of apoptotic/drug resistance-related main control proteins BCL-2 and MDR1 in myeloma cells after transfected with miR-19a-3p.Finally, we found miR-19a acts as an oncogene in MM by promoting cell proliferation/invision and inhibiting apoptosis. Additionally, We further showed that the mRNA and protein of BCL-2 and MDR were upregulated significantly after elevated expression of miR-19a, the process of which was regulated by PTEN/AKT/pAKT-signaling pathway. Our results suggest that miR-19a acted as an oncogenic miRNA by targeting PTEN in myeloma. This novel miR-19a/PTEN/AKT axis sheds new light on the mechanisms underlying apoptosis and invision and may provide potentially therapeutic targets for the treatment of myeloma.
科研通智能强力驱动
Strongly Powered by AbleSci AI